Charles River Laboratories International Inc
XMUN:RV6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Charles River Laboratories International Inc
XMUN:RV6
|
US |
|
Pitney Bowes Inc
NYSE:PBI
|
US |
|
H
|
HSBC Holdings PLC
SWB:HBC1
|
UK |
|
F
|
Fastenal Co
XETRA:FAS
|
US |
|
S
|
Schroders PLC
XBER:PYX
|
UK |
|
S
|
Smoore International Holdings Ltd
OTC:SMORF
|
CN |
|
Enel SpA
F:ENLA
|
IT |
|
Cohort PLC
LSE:CHRT
|
UK |
|
Q
|
Quanta Services Inc
DUS:QAA
|
US |
|
Haier Smart Home Co Ltd
SSE:600690
|
CN |
|
L
|
Localiza Rent a Car SA
OTC:LZRFY
|
BR |
|
B
|
Bayerische Motoren Werke AG
LSE:0O0U
|
DE |
|
K
|
Kao Corp
XBER:KAO
|
JP |
|
First Internet Bancorp
NASDAQ:INBK
|
US |
|
G
|
Global Payments Inc
LSE:0IW7
|
US |
|
K
|
Komercni Banka as
XBER:KONN
|
CZ |
|
HP Inc
NYSE:HPQ
|
US |
|
J
|
Japan Real Estate Investment Corp
F:JUA
|
JP |
|
T
|
Tesco PLC
OTC:TSCDY
|
UK |
|
E
|
Equitable Holdings Inc
XETRA:AXJ
|
US |
Charles River Laboratories International Inc
Charles River Laboratories helps drugmakers and biotech companies test new medicines before they reach patients. It sells laboratory services, research models such as specialty animals, and tools used in early drug discovery and safety testing. Its work sits in the middle of the pharmaceutical development process: customers use Charles River to find drug candidates, test how they behave in the body, and check whether they are likely to be safe enough to move forward. The company makes money mainly by charging for scientific services and by selling the research models and related products that labs need for studies. Its main customers are pharmaceutical companies, biotechnology firms, academic labs, and government or contract research groups. Many customers use Charles River because they want a partner with the facilities, animals, assays, and regulatory expertise needed to run complex studies that they do not want to build in-house. What makes the business model different is that Charles River is not selling a final medicine; it is selling the tools and testing work needed to get medicines developed in the first place. That makes it an important behind-the-scenes supplier in drug development. Its revenue comes from repeated testing programs, long research relationships, and the steady demand for preclinical and safety work that drug developers need before clinical trials.
Charles River Laboratories helps drugmakers and biotech companies test new medicines before they reach patients. It sells laboratory services, research models such as specialty animals, and tools used in early drug discovery and safety testing. Its work sits in the middle of the pharmaceutical development process: customers use Charles River to find drug candidates, test how they behave in the body, and check whether they are likely to be safe enough to move forward.
The company makes money mainly by charging for scientific services and by selling the research models and related products that labs need for studies. Its main customers are pharmaceutical companies, biotechnology firms, academic labs, and government or contract research groups. Many customers use Charles River because they want a partner with the facilities, animals, assays, and regulatory expertise needed to run complex studies that they do not want to build in-house.
What makes the business model different is that Charles River is not selling a final medicine; it is selling the tools and testing work needed to get medicines developed in the first place. That makes it an important behind-the-scenes supplier in drug development. Its revenue comes from repeated testing programs, long research relationships, and the steady demand for preclinical and safety work that drug developers need before clinical trials.
Results: Charles River reported first-quarter revenue of $996 million, with organic revenue down 1.5%, but management said results were in line to slightly better than expected.
Margins: Operating margin fell 280 basis points to 16.3% because of temporary headwinds, including stock compensation tied to the CEO transition, higher NHP costs, and shipment timing.
Outlook: The company reaffirmed full-year organic revenue guidance of down 0.5% to 1.5% and EPS guidance of $10.80 to $11.30, while lowering reported revenue guidance because of weaker FX.
Margin Recovery: Management expects a sharp step-up in margins in the second half of 2026, with full-year operating margin improvement of 120 to 150 basis points.
Demand: DSA demand remained solid with a net book-to-bill of 1.04x and backlog of $1.92 billion, and management said this supports a return to DSA organic growth in the second half.
Strategy: The new CEO outlined a refreshed strategy called “Pathway to Purpose,” centered on efficiency, portfolio reshaping, customer centricity, and technology, including AI and NAMs.
Capital: Charles River completed the CDMO and Cell Solutions divestiture, expects another European site sale in May, and repurchased about $200 million of stock in the quarter.
